Technical Service Platform

Technical Service Platform

Recommended Information

In vitro–differentiated Th1/Th17/Treg cells

In vitro–differentiated Th1/Th17/Treg cells

CD4+ helper T cells (Th cells) serve as mediators of cellular immunity and play a critical role in activating other immune cells, such as B cells and cytotoxic T cells, as well as in regulating immune responses.
Antibody-Dependent Cell-Mediated Cytotoxicity Assay (ADCC)

Antibody-Dependent Cell-Mediated Cytotoxicity Assay (ADCC)

Antibodies, as integral components of the immune system, play a crucial role in defending against disease. Antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the mechanisms by which antibodies exert their effector functions: when IgG antibodies specifically bind via their Fab fragments to antigenic epitopes on the surface of target cells—such as virus-infected cells and tumor cells—the Fc portion of the antibody can engage Fc receptors on effector cells, including natural killer (NK) cells, monocytes–macrophages, and neutrophils, thereby triggering the effector cells’ cytotoxic activity and directly killing the target cells. The ability to elicit ADCC against target cells is an important functional criterion for antibody candidates that are directed against cancer-associated antigens.
Antibody-dependent cellular phagocytosis

Antibody-dependent cellular phagocytosis

Antibody-dependent cellular cytotoxicity (ADCC) is one of the mechanisms by which antibody-based therapies exert their antitumor and other therapeutic effects. Currently, therapeutic strategies aimed at enhancing macrophage responses to therapeutic antibodies have garnered significant attention from researchers, including the identification of novel targets and the development of antibodies with enhanced functionality.
Complement-dependent cytotoxicity (CDC)

Complement-dependent cytotoxicity (CDC)

Complement is a group of heat-labile, enzymatically active proteins found in human and vertebrate serum and tissue fluids, comprising more than 30 soluble and membrane-bound proteins. Complement-dependent cytotoxicity (CDC) refers to the lytic effect on target cells resulting from the formation of a membrane attack complex after complement is activated by specific antibodies that bind to corresponding antigens on the cell membrane via the classical pathway of complement activation. Initially, antibodies bind to complement component C1q, which then triggers the sequential activation of C2 through C9 to form the membrane attack complex, ultimately leading to lysis of the target cell.
Cytokine Release Syndrome Risk Assessment (CRS)

Cytokine Release Syndrome Risk Assessment (CRS)

Cytokine release syndrome (CRS) refers to a hyperactive immune response that occurs following infection with pathogenic microorganisms, leading to the rapid activation of numerous immune cells and the massive release of multiple cytokines—including TNF-α, IL-1, IL-6, IL-12, IFN-α, IFN-β, and IFN-γ—within a short period. This results in a severe systemic inflammatory response syndrome. The excessive production of these cytokines can damage tissues and organs, thereby giving rise to a wide range of clinical manifestations. Currently, the standard approach is to closely monitor and target the specific cytokines that trigger the cytokine storm.
Flow Cytometry-Based Cell Characterization Experiments (FACS)

Flow Cytometry-Based Cell Characterization Experiments (FACS)

The targets of antibody drugs are primarily disease-associated antigens or specific receptor molecules on the cell surface. Competitive binding between ligands and antibodies is assessed by using flow cytometry to determine the population of antigen-positive cells. By employing antigen-presenting cells in these assays, the spatial conformation of surface antigens more closely resembles their in vivo configuration, thereby yielding results that better reflect physiological conditions.

Cytokine Release Syndrome Risk Assessment (CRS)

Cytokine release syndrome (CRS) refers to a hyperactive immune response that occurs following infection with pathogenic microorganisms, leading to the rapid activation of numerous immune cells and the massive release of multiple cytokines—including TNF-α, IL-1, IL-6, IL-12, IFN-α, IFN-β, and IFN-γ—within a short period. This results in a severe systemic inflammatory response syndrome. The excessive production of these cytokines can damage tissues and organs, thereby giving rise to a wide range of clinical manifestations. Currently, the standard approach is to closely monitor and target the specific cytokines that trigger the cytokine storm.

Cytokine release syndrome (CRS) refers to a hyperactive immune response that occurs following infection with pathogenic microorganisms, leading to the rapid activation of numerous immune cells and the massive release of multiple cytokines—including TNF-α, IL-1, IL-6, IL-12, IFN-α, IFN-β, and IFN-γ—within a short period. This results in a severe systemic inflammatory response syndrome. The excessive production of these cytokines can damage tissues and organs, thereby giving rise to a wide range of clinical manifestations. Currently, the standard approach is to closely monitor and target the specific cytokines that trigger the cytokine storm.

 

Service Advantages:

Quality System

1. Strict adherence to subject screening ， Standards for Sample Collection and Management

2. Complete ethical approval documentation that complies with the review requirements of the ethics committee and other regulatory compliance obligations, including corporate audits. Supports on-site client inspections.

3. Professional Cold-Chain Logistics Cooperation system , ensuring the entire sample process Compliant and Efficient Delivery

R&D System

1. Focus in Cell therapy and Gene therapy and large-molecule drug development

2. Continuously optimize standardized preparation processes and lead industry service standards.

3. Innovate service models and expand the boundaries of research applications

Professional Team

1.  A seasoned R&D team and a mature, standardized cell preparation process and manufacturing system.

2. Standardization covering both Chinese and international populations Donor Registry and management system

Core Resources

1. World-class production and service equipment, as well as laboratory facilities, nearly 1,000-square-meter R&D base

2. Establish multiple clinical collaboration centers, with the East China region as the leading hub, covering tertiary hospitals nationwide and high-quality GCP management centers.

3. Our in-house specialized project team can provide clients with services such as regulatory interpretation, policy analysis, domestic-investor qualification determination, and approval for foreign-invested cooperation. ， Providing one-stop compliance support

 

Keyword

Previous page:

Complement-dependent cytotoxicity (CDC)

Flow Cytometry-Based Cell Characterization Experiments (FACS)

:Next page

Previous page:

Complement-dependent cytotoxicity (CDC)

Next page:

Flow Cytometry-Based Cell Characterization Experiments (FACS)